Date: 2016-12-09
Type of information: Nomination
Compound:
Company: Enterome Bioscience (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 9, 2016, Enterome announced the appointments of Jai Patel, Ph.D. as Chief Medical Officer (CMO), and Roger J. Garceau, MD as Non-executive Director. Drs Patel and Garceau bring significant experience in clinical pharmaceutical development and reinforce Enterome’s leadership team as the company progresses its lead therapeutic and diagnostic projects, including EB8018 for Crohn’s disease, into and through clinical development. Dr. Patel joins Enterome with over 25 years’ industry experience and a strong background in international clinical development and regulatory affairs. He was most recently Chief Medical & Scientific Officer at NephroGenex and, before that, spent over 20 years at GSK where he held positions of increasing responsibility, serving as Vice President across R&D disciplines including clinical research, medical affairs and global regulatory affairs. He received his medical training at the University of London and is a member of the UK Royal College of Physicians. Dr. Garceau brings over 30 years’ of pharmaceutical development experience to Enterome. He previously served as CMO and Executive Vice President of Research & Development at NPS Pharmaceuticals, Inc. Prior to this, he held executive clinical and development roles at Sanofi-Aventis, Aventis and Pharmacia-Upjohn (Pfizer), where he contributed to a number of successful new pharmaceutical marketing applications. Dr. Garceau received his Doctorate of Medicine from the University of Massachusetts Medical School.
Financial terms:
Latest news:
